Traders should consider the arbitrage spread between the current price and the $3.16 cash offer, accounting for deal risks. Key catalysts are the proxy filing and shareholder vote. Monitor regulatory approvals and any competing bids. The CVRs provide additional upside tied to net sales milestones.
Price Chart
Executive Summary
Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus contingent milestone payments of up to $100 million, representing a total equity value of up to approximately $1.1 billion. The upfront cash consideration offers a 58% premium to the closing price on April 30, 2026. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Acquisition price of $3.16 per share in cash, plus CVRs for up to $100 million in aggregate milestone payments
- Total equity value up to approximately $1.1 billion on a fully diluted basis
- Premium of 58% to Esperion's closing stock price on April 30, 2026
- Board unanimously approved; recommends shareholders vote in favor
- Expected to close in Q3 2026
- Debt financing from Pharmakon Advisors; no financing condition
Financial Impact
Upfront cash of $3.16 per share (58% premium) plus contingent milestone payments up to $0.39 per share, for total potential value of ~$3.55 per share
Risk Factors
- Shareholder approval required; potential opposition
- Regulatory approvals needed (HSR, etc.)
- Deal termination risk; if conditions not met, stock may drop back to pre-announcement levels
- CVR payments are contingent on commercial performance and may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access